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Abstract To comprehensively evaluate the therapeutic ef-
fects on both functional and structural outcomes, we per-
formed a meta-analysis of preclinical data on stem cell therapy
in intracranial hemorrhage, thus providing optimal evidence
and instruction for clinical translation. We searched online
databases to identify eligible studies based on unmodified
stem cell transplantation in intracranial hemorrhage (ICH).
From each study, we extracted data regarding neurobehavioral
and histological outcomes in order to analyze the comprehen-
sive effective sizes according to the most important clinical
parameters (seven indices) and to explore any potential corre-
lation through meta-regression. We analyzed 40 eligible stud-
ies including 1021 animals and found a significant improve-
ment in both behavioral and structural outcomes with the me-
dian effect size of 1.77 for modified Neurological Severity
Score, 1.16 for the modified placement test, 1.82 for the
rotarod test, and 1.24 for tissue loss reduction. The meta-
regression results revealed that intracerebral administration
was the most effective for behavioral and structural recovery
post-ICH; mesenchymal stem cells shared comparable
therapeutic effects with neural stem cells. Delayed therapy,
applied more than 1 week after ICH, showed the greatest
improvement of structural outcomes. Stem cell therapy
showed significant improvement on behavioral and structural
outcomes of ICH animals with relatively large effect sizes.
However, the practical efficacy of the therapy is likely to be
lower considering poor study quality and non-negligible pub-
lication bias. Further, future research should interpret animal
results cautiously considering the limited internal and external
validity when referring to the design of both animal studies
and clinical trials.
Keywords Intracerebral hemorrhage . Stem cells .
Meta-analysis . Clinical translation
Introduction
Intracerebral hemorrhage (ICH), which results from rupture of
blood vessels in the brain, remains a public health concern
because it leads to high rates of mortality and disability in
adults [1]. Hematoma expansion and brain edema are two
important complications that might occur during the acute
and subacute phases of ICH; both are known to exacerbate
brain injury [2, 3]. Management of ICH is largely carried out
via mechanical removal of the hematoma, pharmacological
prevention of edema formation, and reduction in intracranial
pressure. The intent of all of these methods is to limit further
brain injury and associated complications. Unfortunately,
compared with ischemic stroke, ICH has received less re-
search attention, and, to date, no currently available medical
therapy has shown a consistent or unambiguous benefit in
functional outcomes after ICH [4, 5].
Stem cells—including embryonic stem cells (ESCs), so-
matic stem cells, and induced pluripotent stem cells
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(iPSCs)—are characterized by their capacity for self-renewal
and multiple differentiation. Mesenchymal stem cells (MSCs)
have long been used in preclinical and clinical research [6, 7],
and stem cell therapy has become one of the most promising
strategies for the treatment of comprehensive human diseases,
such as ischemic heart disease, autoimmune diseases, and
neurological disorders [8–11]. The general intent of stem cell
therapy is to replace lost cells or restore the function of dam-
aged tissues by introducing with the capacity of secreting
multiple growth factors, cytokines, and neurotrophins. How-
ever, the underlying mechanisms are far more complex and
still not fully understood at present [12–14].
A number of reports on stem cell transplantation in ICH
animal models indicate improved neurobehaviors or atten-
uation of the hematoma [15–17]. Among various stem
cells, MSCs and neural stem cells (NSCs) are the most
widely used and offer great promise in ICH repair. How-
ever, the administration dose, route, time interval, cell
source, type, manipulation, and quality score in each study
are so divergent that the overall therapeutic effect is diffi-
cult to evaluate. Consequently, the optimal pattern of cell
therapy remains unclear [18]. To clarify the current situa-
tion and future research directions in cell therapy as a treat-
ment for ICH, we collected data from all relevant studies
and performed a meta-analysis to quantify both the func-
tional and structural efficacy of stem cell therapy. Among
these studies, the most widely used empirical tests to assess
behavioral outcome of ICH include the modified neurolog-
ical severity score (mNSS), modified limb placement test
(mLPT), and rotarod test [19, 20]. The studies included in
the meta-analysis are graded strictly according to Collabo-
rative Approach to Meta-Analysis and Review of Animal




Studies of stem cell-based therapy for ICH animal
models were retrieved from PubMed and Medline
through April 2015 using the following search terms:
(progenitor OR stem OR bone marrow OR mesenchymal
OR haematopoietic) AND (basal ganglion hemorrhage
OR brain hemorrhage OR brain ventricle hemorrhage
OR cerebellum hemorrhage OR intracranial hemorrhage
OR hemorrhage stroke). Two researchers worked inde-
pendently on these searches (Yang Hu and Na Liu). Re-
trieved articles and abstracts, including secondary refer-
ences, were thoroughly scanned and reviewed by the two
researchers, either. Eligible studies were reviewed in
duplicate to determine whether or not to be included in
the meta-analysis.
Inclusion and Exclusion Criteria
The meta-analysis included controlled studies that compared
neurobehavioral outcomes—with or without structural out-
comes—in wild-type (nontransgenic) animal groups. In these
studies, ICH was induced using autologous blood or collage-
nase injection, after which subjects were treated with alloge-
neic or autologous stem cells and a placebo (saline, culture
medium, or similar vehicle). The meta-analysis excluded stud-
ies that used nontraumatic models of hemmorrhagic injury or
individual comparisons that were not reported or from which
we could not calculate the number of animals, the mean out-
come, or the variance in each group. We also excluded studies
that used substantially manipulated stem cells, including cells
differentiated into mature neural cells, co-transplanted with
other stem cells, or transfected with genes other than labeling
or tracing markers.
Data Collection
The following items from the eligible studies were indepen-
dently extracted by the two researchers: general study infor-
mation (first author, publication date), ICH model, cell char-
acteristics (cell type, source, dose, delivery route), recipient
animal species, functional outcome (neurobehavioral score
measured on any scale, modified limb placement test, rotarod
test), structural outcome (brain water content or tissue loss
reduction), and study quality index.
From each experiment, the researchers extracted, without
exception, all available data from reported outcomes avail-
able, text, and graphs. When only graphic presentations were
available, values for mean and standard deviation (SD) were
obtained via calibrating images using GetData Graph Digitiz-
er software. If the study included more than one experimental
group differentiated by delivery time or cell number that was
compared against a common control group, these parallel
groups would be included separately as independent experi-
ments and the control group size divided equally among the
numbers of treatment groups. If the SD was not directly re-
ported, it was calculated by multiplying the reported standard
error (SE) by the square root of the group size. Where func-
tional outcome was measured at different times, only the most
recent one was extracted.
Methodological Quality of Studies
The quality of each experiment was assessed according to the
CAMARADES checklists, which consist of the following: (1)
publication in a peer-reviewed journal, (2) control of animals’
temperature, (3) randomized treatment allocation, (4)
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treatment allocation concealment, (5) blind assessment of out-
come, (6) avoidance of anesthetics with known marked intrin-
sic neuroprotective activity such as ketamine, (7) reporting of
a sample size calculation, (8) statement of compliance with
regulatory requirements, (9) statement of potential conflicts of
interest, and (10) use of animals with relevant comorbidities.
Statistical Analyses
Effect size was calculated to be the absolute difference with
95 % confidence interval (CI) between stem cell treated ani-
mals and comparable controls. For the rotarod test, in contrast
to the other three measures, outcome values were multiplied
by −1 because the value was positively correlated with its
outcome. The DerSimonian-Laird random meta-analysis
model and Hedges calculation were adopted to determine a
comprehensive estimation of effect size with standard mean
differences, andmeta-analysis was performed using Stata soft-
ware (version 12.1). Generally, an effect size of 0.2 was de-
fined as a small effect, 0.5 as medium and 0.8 as large. A
probability value of P<0.05 was considered statistically sig-
nificant. Seven intriguing clinical parameters were used to
stratify the effect size: cell source (autologous, allogeneic, or
xenogeneic); cell type (NSCs, MSCs, or other stem cells); cell
dose (<1E6, 1E6–5E6, >5E6); delivery time (0–8 h, 24 h, 1–7
days, or >7 days); randomization; blind review by operator;
and total quality score. Meta-regression and pre-specified sub-
group analysis were used to explore the potential relationships
betweenmNSS and tissue loss and the aforementioned param-
eters. Publication bias was examined using funnel plots, and
significant publication bias was assessed using Egger
regression. If necessary, any non-negligible bias would be
corrected using the Duval and Tweedie trim-and-fill approach.
Results
Study Characteristics
Electronic searching identified 440 articles in PubMed and
173 articles in EMBASE. From among these, 40 eligible stud-
ies containing 589 cell treatment animals and 432 comparable
controls were eventually included in our meta-analysis
(Fig. 1). Twenty of these studies demonstrated improvement
in mNSS, and seven of the 11 studies reported decreased tis-
sue loss. The vast majority of the studies (62.5 %) used MSCs
derived from bone marrow, adipose tissue, or umbilical blood,
and, except for two studies that used iPSCs, the remaining
studies used NSCs. In 33 of the 40 studies, a collagenase-
induced ICH model was adopted, while the remaining studies
adopted an autologous blood-induced ICH model.
Quality Score
The quality scores varied from 1 to 7, with a mean value of
4.45. According to our statistical results, all the articles were
published in a peer-reviewed journal; 37.5 % described con-
trol of temperature, 75 % declared randomization to treatment
group, 60 % stressed blind assessment of outcome, 50 %
avoided usage of ketamine as anesthetics, 90 % claimed com-
pliance with animal welfare regulations, and 30 % stated a
conflict of interest (Table 1; SI File).
Excluded  (n=540)
No cell therapy (n= 125 )
No ICH (n= 63 )
No functional outcome (n= 70 )
Others (n= 282 )
Articles from Pubmed(n=440)Articles from EMBASE(n=173)
Full text reviewed (n=73)
Excluded  (n=33 )
No functional outcome (n= 8 )
Clinical trials (n= 3 )
Modified cells (n= 2 )
Others (n=20 )
Studies included (n=40)
Fig. 1 Flow diagram of preferred
reporting items for systematic
reviews and meta-analyses
(PRISMA) (created by Microsoft
Word)
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Meta-analysis
Overall, use of stem cell therapy showed an improvement in
both functional and structural outcomes post-ICH, and all four
effect sizes were statistically significant (1.77 for mNSS, 1.16
for MLPT, 1.82 for RR, and 1.24 for tissue loss reduction)
(Fig. 2). Observed heterogeneity was higher than what would
be expected from sampling error alone and could not be ig-
nored (τ2=0.6777, I2=61 % for mNSS; τ2=0.1751, I2=
42.1 % for MLPT; τ2=1.6451, I2=86.7 % for RR; τ2=
0.1833, I2=35.4 % for tissue loss reduction). For the two
outcomes with the largest amount of published data—mNSS
and tissue loss reduction—meta-regression was used to ex-
plore potential contributions to heterogeneity of the parame-
ters mentioned above.
Meta-regression for Functional and Structural Outcomes
For mNSS, publication year remained the only significant
predictor (P=0.036); the more recently the research was con-
ducted, the larger the effect sizes were (Fig. 3a). For tissue loss
reduction, administration route and time remained as signifi-
cant predictors (P=0.005 for administration route; P=0.002
for administration time); in fact, intracerebral (ICV) injection
was demonstrated to be the most effective route for improve-
ment of both mNSS and tissue loss reduction, more so than
intravenous (IV) and intra-arterial (IA) injections. In tissue
loss reduction, cell therapy initiated more than 1 week post-
ICH showed the greatest difference, followed next by cell
therapy initiated within 1 week post-ICH, and then therapy
initiated with 24 h (mean effect size 3.027 vs 1.270 vs
0.942; P=0.002; Fig. 3b). None of the other clinical parame-
ters were predictors for effect size, nor were any of the three
quality parameters (total quality score, randomization, and
allocation concealment). Additionally, subgroup analysis
revealed that MSCs shared a comparable effect size with
NSCs, as did allogenic cells with xenogenic cells (Tables 2
and 3).
Publication Bias
Visual inspection of funnel plots of mNSS and MLPT re-
vealed asymmetry. This was consistent with the results from
the Egger test, which suggested prominent publication bias to
the left of the estimate (P=0.004 for mNSS; P=0.001 for
MLPT). However, after correcting for the bias, the pooled
analysis incorporating the hypothetical studies remained sta-
tistically significant, and all four calibrated effect sizes exceed
1 (1.367 for mNSS and 1.053 for MLPT).
Discussion
This meta-analysis including 40 studies and 1021 animals
suggests the following: (1) ICH animals benefited greatly
from stem cell therapy, with treatment using both NSCs and
MSCs exhibiting statistically significant improvement in
functional and structural outcomes. (2) ICV proved to be the
most effective administration route compared with IVor IA to
improve mNSS and decrease tissue loss. (3) Allogenic and
xenogenic cells exhibited similarly beneficial effect size for
mNSS, although the former facilitated lesion site recovery to a
larger extent. (4) Intervention time was positively correlated
with effect size in tissue loss reduction but not in mNSS. (5)
Stem cell-based therapy shows promise in treating ICH ani-
mals based on our study, but determining the efficacy is inev-
itably confounded by poor study quality and publication bias.
Therefore, our conclusions should be tested in more rigorous-
ly designed studies and carefully interpreted in relation to the
design of future clinical translation or animal studies.
The categories of stem cells already used for ICH animals
are NSCs [16, 17], ESCs [22], human MSCs [23], human
bone marrow stromal cells (HBMSCs) [24], adipose-derived
stem cells [25], human umbilical cord blood cells (HUCBCs),
and human iPSCs [26]. Our meta-analysis included all but
ESCs, with the majority being MSCs derived from various
tissues. Our pre-specified subgroup analysis stratified by cell
type showed that MSCs had a greater positive impact on
mNSS, while NSCs were more effective in decreasing tissue
loss. Although post hoc meta-regression detected no correla-
tion between cell type and effect size, this distinction between
the two cells types might be explained by their different ther-
apeutic mechanisms. To be specific, because of the unique
capacity of NSCs to differentiate into functional neural cells,
reduced tissue loss might result from donor NSCs replacing
damaged neurons, although very few studies have rigorously
examined the electrophysiological and transmitter synthesis
function of transplanted NSCs in vivo [27, 28]. But again, this
Table 1 Percentage of included studies satisfying each criterion of
CAMARADES checklists
Quality score criterion Percentage of qualified
studies (%)
Published in peer-reviewed journal 100
Control of temperature 37.5
Randomization to treatment group 75
Allocation concealment 2.5
Blinded assessment of outcome 60
Avoidance neuroprotective anesthetics 50
Sample size calculation 0
Compliance with animal welfare regulations 90
Statement of conflict of interest 30
Use of animals with relevant comorbidities 0
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is likely the result of NSC secretion of several cytokines after
ICH, which, as recent studies have shown, attenuate systemic
inflammatory response [10, 29, 30]. Even with these recent
studies, this unique mechanism requires further exploration in
future research work. Compared with NSCs, the effectiveness
of MSCs as documented in models of neurological disease is
attributed mainly to the cells’ ability to secrete various
neurotrophins, cytokines, or growth factors, including brain-
derived neurotrophic factor (BDNF), nerve growth factor
(NGF), basic fibroblast growth factor (bFGF), and vascular
endothelial growth factor (VEGF), all of which possibly con-
tribute to the functional recovery of the subventricular zone
(SVZ) in the adult central nervous system [23, 31, 32]. The
number of transplanted MSCs that express physical and bio-
chemical characteristics of neural cells is extremely low, so
virtually none of them are able to be integrated into functional
neural circuitry [33]. Nevertheless, the underlying mecha-
nisms are far more complex and still not fully understood at
present. Given the current state of research, we find thatMSCs
share comparable therapeutic effects with NSCs in ICH,
which challenges the obsolete view that NSCs might be
considered the most appropriate cells for treating nervous
system diseases like ICH. Therefore, MSCs seem to be a
promising cell source for future clinical application
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Fig. 2 Forest plot shows mean effect size and 95 %CI for a mNSS, b tissue loss reduction, cMLPT, and d RR. mNSS modified neurological severity
score, MLPT modified limb placement test, RR rotarod test, ICV intracerebral, IV intravenous, IA intra-artery (created by stata)
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because of their similarity to NSCs in their effects, and
yet they require a less invasive and delicate isolation pro-
cedures than NSCs [34].
Of additional concern are the immunological issues com-
monly associated with the process of allogenic or xenogenic
cell transplantation. Once exogenous cells trigger an intrinsic
immune rejection in vivo, the transplanted cells will be elim-
inated by the activated immune system, a process that not only
destroys the cell functions, but also causes damage to the hosts
[35, 36]. Considering that majority of cells included in our
analysis were MSCs, which can exert overt regulation on the
host’s immune system, no obvious immune rejections were
reported, even in the xenogenic cell transplantation group
not simultaneously treated with immunosuppressants. In our
subgroup analysis, the difference in effect size between allo-
genic and xenogenic cells was not statistically significant
(P>0.05).
Administration route and dose are typically the focus if cell
therapy is applied in clinical situations. In our analysis, the
intracerebral route seems to have a distinct advantage over
both the IVand intracarotid routes. Compared with ICV, either
IV or IA is relatively less invasive and more convenient to
manipulate. Temporarily disregarding the inconvenience of
ICV, it does show superiorities over IV route in that it can
rapidly and directly target the lesion site while avoiding spleen
phagocytosis and retardation of brain blood barrier retention
[37–39]. More importantly, it is possible to combine cell ther-
apy administered through ICV with hematoma evacuation af-
ter ICH [40, 41]. At the same time, cell viability might de-
crease significantly once the cells are exposed directly via ICV




































Fig. 3 Meta-regression results for a effect size of mNSS positively
correlated with publication year and b effect size of tissue loss
reduction positively correlated with administration time (created by stata)
Table 2 Results of mNSS from subgroup analysis of parameters
Parameters
Dose <1E6 1E6–5E6 >5E6
1.773 (1.134, 2.411) 1.954 (1.378, 2.530) 1.273 (0.516, 2.029) NS
Route ICV IV IA
2.344 (1.617, 3.071) 1.384 (1.010, 1.757) 1.049 (0.270, 1.829) P=0.036
Time 0–8 h 24 h >1 day–1 week >1 week
4.071 (1.784, 6.358) 1.500 (1.086, 1.915) 2.373 (1.652, 3.094) 0.543 (−0.215, 1.300) NS
Immunity Allogenic Xenogenic
1.950 (1.210, 2.690) 1.617 (1.217, 2.017) NS
Type NSC MSC IPS
1.459 (0.728, 2.190) 1.896 (1.418, 2.374) 1.960 (−0.843, 4.763) NS
Blinding Nonblinded Blinded
1.655 (1.047, 2.264) 1.890 (1.368, 2.413) NS
Randomization Nonrandomized Randomized
1.926 (0.861, 2.991) 1.769 (1.349, 2.189) NS
Effect size of mNSS from subgroup analysis of clinical parameters presented as mean with 95 % confidence interval
ICV intracerebral, IV intravenous, IA intra-artery, NS not significant
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exploring innovative and effective alternative delivery routes
such as intranasal delivery might be a useful future research
direction. The majority of the included studies tended to initi-
ate the cell therapy at 24 h post-ICH, followed by therapy
initiation within 1 week post-ICH; only four exceeded more
than 1 month before beginning treatment, and two of those did
not begin treatment until 2 months post-ICH. We found a
positive correlation between intervention time and structural
effect size, an observation that might be explained by the fact
that a substantial number of studies conducted a final structur-
al assessment before reaching the plateau recovery phase.
However, it is important to keep in mind that subgroup
analyses can only generate hypotheses rather than
confirming them.
Assessment of themethodological quality of animal studies
should follow strict criteria regarding clinical trials because of
the potential that the design of these trials might influence
their results [21]. The average quality score according to the
CAMARADES list was lower than we had expected. The
percentage of descriptive randomization and blindness were
75 and 60, respectively, and none of the studies explicitly
stated the specific procedures followed in conducting the ex-
periments. Additionally, half of the studies adopted ketamine
as the anesthetic regardless of its well-known neuroprotective
effects. Intriguingly, randomization, blinding, and total quality
score were not significant predictors for effect size, which can
be partially attributed to the ambiguous description of the
methods. As a result, we could not predict the effect size for
subsequent studies based on quality scores. To reduce the risk
of bias and given this evidence of the poor reporting of
measures, we encourage future research to report both detailed
methodology and measures performance in the field. Both
Funnel plots and Egger tests detected obvious publication bi-
as, so a trim-and-fill approach was adopted to correct the bias,
although the modified effect sizes were still remarkable. As
might be expected, studies reporting more positive outcomes
are more likely to be accepted for publication, especially in
animal studies.
There is significant work to be done when it comes to
clinical translation [42]. First of all, the study subjects are
primarily rats, which share limited similarities with human
beings in anatomical and biochemical properties, unlike por-
cines or primates, which can mimic human pathological pro-
cess more vividly and precisely [43, 44]. Thus, because the
neurobehavioral outcomes for rats cannot be directly extended
to human beings, more reliable results could be obtained by
using multiple species. Secondly, although ICH is generally
the result of ruptured vessels affected by hypertension-related
degenerative changes or the natural course of cerebral amyloid
angiopathy, current study models are almost entirely based on
healthy animals without any chronic comorbidities, letting
alone hypertension [45]. Furthermore, the majority of ICH
patients are elderly, while study animals are selected from a
fixed age group with a high proportion of youngsters. In terms
of the meta-analysis itself, the internal and external validity
are obviously confounded by poor study quality and non-
negligible publication bias. Consequently, the efficacy of stem
cell therapy for ICH will be amplified to some extent because
studies that remain more often contain neutral or negative
data.
Table 3 Results of tissue loss
reduction from subgroup analysis
of parameters
Parameters
Dose <1E6 1E6–5E6 >5E6
1.147 (0.208, 2.087) 1.332 (0.907, 1.756) 0.753 (−0.212, 1.717) NS
Route ICV IV IA
2.174 (1.282, 3.065) 0.955 (0.621, 1.290) 0.856 (−0.120, 1.833) P=0.005
Time 24 h >1 day–1 week >1 week
0.942 (0.606, 1.278) 1.270 (0.648, 1.892) 3.027 (2.062, 3.993) P=0.002
Immunity Allogenic Xenogenic
1.882 (0.906, 2.859) 0.984 (0.654, 1.315) NS
Type NSC MSC
1.557 (0.803, 2.312) 1.189 (0.790, 1.588) NS
Blinding Nonblinded Blinded
1.225 (0.712, 1.738) 1.269 (0.740, 1.797) NS
Randomization Nonrandomized Randomized
1.137 (0.700, 1.573) 1.293 (0.718, 1.868) NS
Location Toatal Striatum
2.143 (1.200, 3.085) 0.973 (0.659, 1.286) P=0.008
Effect size of tissue loss reduction from subgroup analysis of clinical parameters presented as mean with 95 %
confidence interval
ICV intracerebral, IV intravenous, IA intra-artery, NS not significant
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Although several reviews and meta-analyses focusing on
cell therapy for neurological diseases have been published,
this is the first meta-analysis to concentrate specifically on
stem cells used for ICH in animal models [46, 47]. Although
the obvious effect size for ischemic stroke of MSCs alone or
for all stem cells has been emphasized, the pathophysiological
features of ischemic and hemorrhagic stroke diverge in many
aspects, so great caution should be taken when comparing
findings for each disease [48].
According to our study, stem cell-based therapies may offer
promise in treating ICH, and, the therapeutic effect of stem
cells in this application seems obvious based on preclinical
research. However, future research should interpret animal
results cautiously considering the limited internal and external
validity when referring to the design of both animal studies
and clinical trials.
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Glossary
CAMARADES Collaborative Approach to Meta-Analysis
and Review of Animal Data from Experi-
mental Stroke
ICH Intracerebral hemorrhage
IPS Induced pluripotent stem cell
MLPT Modified limb placement test
mNSS Modified neurological severity score
MSC Mesenchymal stem cell
NSC Neural stem cell
RR Rotarod test
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